EUR 23.6
(1.72%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 6.90 EUR | 1.32% |
2022 | 6.80 EUR | 425.36% |
2021 | -2.09 EUR | 87.29% |
2020 | -16.44 EUR | -734.75% |
2019 | 2.59 EUR | -70.06% |
2018 | 8.65 EUR | 16.26% |
2017 | 7.44 EUR | -60.21% |
2016 | 18.70 EUR | -3.06% |
2015 | 19.29 EUR | 1507.5% |
2014 | 1.20 EUR | -25.47% |
2013 | 1.61 EUR | -56.49% |
2012 | 3.70 EUR | 76.19% |
2011 | 2.10 EUR | -12.5% |
2010 | 2.40 EUR | 84.62% |
2009 | 1.30 EUR | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 17.41 EUR | 0.0% |
2023 FY | - EUR | 1.32% |
2023 Q4 | 10.50 EUR | 0.0% |
2023 Q2 | -3.60 EUR | 0.0% |
2022 Q4 | 15.21 EUR | 0.0% |
2022 FY | - EUR | 425.36% |
2022 Q2 | 1.00 EUR | 0.0% |
2021 Q2 | 1.00 EUR | 0.0% |
2021 FY | - EUR | 87.29% |
2021 Q4 | 1.00 EUR | 0.0% |
2020 Q2 | 1.00 EUR | 0.0% |
2020 Q4 | 1.00 EUR | 0.0% |
2020 FY | - EUR | -734.75% |
2019 Q2 | -4.26 EUR | 0.0% |
2019 FY | - EUR | -70.06% |
2019 Q4 | 0.99 EUR | 0.0% |
2018 Q4 | -4.40 EUR | 0.0% |
2018 FY | - EUR | 16.26% |
2018 Q2 | 13.10 EUR | 0.0% |
2017 Q2 | -0.50 EUR | 0.0% |
2017 FY | - EUR | -60.21% |
2017 Q4 | 8.17 EUR | 0.0% |
2016 Q4 | 14.06 EUR | 0.0% |
2016 FY | - EUR | -3.06% |
2016 Q2 | 4.60 EUR | 0.0% |
2015 Q4 | 18.76 EUR | 0.0% |
2015 Q2 | 0.53 EUR | 0.0% |
2015 FY | - EUR | 1507.5% |
2014 FY | - EUR | -25.47% |
2014 Q2 | 1.12 EUR | 0.0% |
2014 Q4 | 0.10 EUR | 0.0% |
2013 FY | - EUR | -56.49% |
2013 Q4 | 0.55 EUR | 0.0% |
2013 Q2 | 1.06 EUR | 0.0% |
2012 Q4 | 0.23 EUR | 0.0% |
2012 Q2 | - EUR | 0.0% |
2012 Q1 | - EUR | 0.0% |
2012 FY | - EUR | 76.19% |
2012 Q3 | 0.23 EUR | 0.0% |
2011 FY | - EUR | -12.5% |
2010 FY | - EUR | 84.62% |
2009 FY | - EUR | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Apontis Pharma AG | -1.33 EUR | 618.797% |
Dermapharm Holding SE | 1.16 EUR | -494.828% |
Evotec SE | -0.47 EUR | 1568.085% |
MERCK Kommanditgesellschaft auf Aktien | 6.50 EUR | -6.154% |
PharmaSGP Holding SE | 1.37 EUR | -403.65% |
SynBiotic SE | -2.24 EUR | 408.036% |